

**Proxy for resolutions to be taken in the Annual General Meeting
of shareholders of Pharming Group N.V.**

Proxy for the Annual General Meeting of shareholders as organised by Pharming Group N.V. ("the Company") and to be held on Wednesday June 11, 2025, at 14:00 CEST (hereafter also the "AGM").

THE UNDERSIGNED:

_____, a company / private person residing at _____,
acting as holder of _____ shares in **Pharming Group N.V.**, a public company incorporated and existing under the laws of the Netherlands, having its registered office in Leiden, the Netherlands;

HEREBY GRANTS FULL PROXY AND POWER OF ATTORNEY TO:

- Each member of the Board of Directors of the Company; or
- Mr P.C.S. van der Bijl, civil law notary (notaris) at NautaDutilh N.V., or a substitute to be designated by him (the "Notary").

to represent the undersigned, with the right of substitution, at the AGM and to vote on behalf of the undersigned with regard to any and all matters on the agenda, with all powers that the undersigned would be able to execute if personally attending the AGM, in accordance with the voting instructions as specified at page 2 of this proxy.

This proxy is only valid if (a) duly signed, (b) the undersigned has registered for the AGM in accordance with the procedure set out in the Notice to Convene as published on April 30, 2025 (the "Notice to Convene") and (c) the undersigned attaches either (i) the registration certificate received from ABN AMRO, or (ii) a written confirmation from its intermediary (as defined in the "Wet Giraal Effectenverkeer") confirming that the undersigned was a shareholder on the Record Time, or (iii) an Acknowledgement of Receipt for non-traded shares, all as described in the Notice to Convene.

This proxy is subject to the following conditions:

- in the absence of a selection of a proxyholder above, or the name details of a third party proxyholder, the undersigned will be considered to have granted a proxy and power of attorney to the Notary;
- the agenda items are stated in this proxy in abbreviated form; the full agenda as set out in the Notice to Convene, as incorporated herein by this reference, is leading for the interpretation of each agenda item and the proposed resolution;
- if no voting instruction, or a conflicting voting instruction, is given in this proxy for any or all of the items on the agenda, the undersigned shall be deemed to have instructed the proxyholder to vote 'in favour' of the relevant agenda item(s) as set out in the Notice to Convene;
- this proxy is governed exclusively by the laws of The Netherlands.

Voting instructions:

		<u>In favour</u>	<u>Against</u>	<u>Abstain</u>
Agenda item	Summary			
2 b)	Remuneration report for 2024 (<i>advisory vote</i>)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2 e)	Proposal to adopt the financial statements for 2024	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2 f)	Proposal to discharge the members of the Board of Directors for their responsibilities in 2024	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	Proposal, by way of binding nomination, to appoint Dr. Elaine Sullivan as new Non-Executive Director, for a period of four years	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4a)	Proposal, by way of binding nomination, to reappoint Mrs. Jabine van der Meijs as Non-Executive Director for four years	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4b)	Proposal, by way of binding nomination, to reappoint Mr. Leonard Kruimer as Non-Executive Director for four years	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5)	Proposal to re-appoint Deloitte Accountants B.V. as the external auditor of the Company for the financial year 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6)	Authorization of the Board of Directors to issue shares, or rights to acquire shares, up to 10% of the issued capital, and to exclude pre-emptive rights, for general corporate purposes (including equity incentive plans).	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7)	Authorization of the Board of Directors to repurchase shares in the Company.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Signed in (*place:*) _____ on (*date:*) _____ 2025

Signature: _____

Name: